Development of Second-Generation Small-Molecule RhoA Inhibitors with Enhanced Water Solubility, Tissue Potency, and Significant in vivo Efficacy
RhoA, a member of the Rho GTPases, is involved in a variety of cellular functions and could be a suitable therapeutic target for the treatment of cardiovascular diseases. However, few small-molecule RhoA inhibitors have been reported. Based on our previously reported lead compounds, 32 new 2-substituted quinoline (or quinoxaline) derivatives were synthesized and tested in biological assays. Six compounds showed high RhoA inhibitory activities, with IC50 values of 1.17-1.84µM. Among these, (E)-3-(3-(ethyl(quinolin-2-yl)amino)phenyl)acrylic acid (26b) and (E)-3-(3-(butyl(quinolin-2-yl)amino)phenyl)acrylic acid (26d) demonstrated noticeable vasorelaxation effects against phenylephrine-induced contraction in thoracic aorta artery rings, and compound 26b had good water solubility and showed significant in vivo efficacy, which was similar to that of 5-(1,4-diazepane-1-sulfonyl)isoquinoline (fasudil) in a subarachnoid hemorrhage-cardiovascular model. To the best of our knowledge, compound 26b is the first example of a small- molecule RhoA inhibitor with potent in vivo efficacy, which could serve as a good lead for designing cardiovascular agents..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
ChemMedChem - 10(2015), 1, Seite 193 |
| Sprache: |
Deutsch |
|---|
| Beteiligte Personen: |
Sheng Ma [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| RVK: |
|---|
| doi: |
10.1002/cmdc.201402386 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC196176928X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC196176928X | ||
| 003 | DE-627 | ||
| 005 | 20230516200944.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||ger c | ||
| 024 | 7 | |a 10.1002/cmdc.201402386 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC196176928X | ||
| 035 | |a (DE-599)GBVOLC196176928X | ||
| 035 | |a (PRQ)proquest_journals_16392946283 | ||
| 035 | |a (KEY)0595910120150000010000100193developmentofsecondgenerationsmallmoleculerhoainhi | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 082 | 0 | 4 | |a 610 |q DE-101 |
| 082 | 0 | 4 | |a 540 |q AVZ |
| 084 | |a PHARM |2 fid | ||
| 084 | |a VA 3569 |q AVZ |2 rvk | ||
| 084 | |a 44.42 |2 bkl | ||
| 084 | |a 35.07 |2 bkl | ||
| 084 | |a 58.28 |2 bkl | ||
| 100 | 0 | |a Sheng Ma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Second-Generation Small-Molecule RhoA Inhibitors with Enhanced Water Solubility, Tissue Potency, and Significant in vivo Efficacy |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a RhoA, a member of the Rho GTPases, is involved in a variety of cellular functions and could be a suitable therapeutic target for the treatment of cardiovascular diseases. However, few small-molecule RhoA inhibitors have been reported. Based on our previously reported lead compounds, 32 new 2-substituted quinoline (or quinoxaline) derivatives were synthesized and tested in biological assays. Six compounds showed high RhoA inhibitory activities, with IC50 values of 1.17-1.84µM. Among these, (E)-3-(3-(ethyl(quinolin-2-yl)amino)phenyl)acrylic acid (26b) and (E)-3-(3-(butyl(quinolin-2-yl)amino)phenyl)acrylic acid (26d) demonstrated noticeable vasorelaxation effects against phenylephrine-induced contraction in thoracic aorta artery rings, and compound 26b had good water solubility and showed significant in vivo efficacy, which was similar to that of 5-(1,4-diazepane-1-sulfonyl)isoquinoline (fasudil) in a subarachnoid hemorrhage-cardiovascular model. To the best of our knowledge, compound 26b is the first example of a small- molecule RhoA inhibitor with potent in vivo efficacy, which could serve as a good lead for designing cardiovascular agents. | ||
| 700 | 0 | |a Jing Deng |4 oth | |
| 700 | 0 | |a Baoli Li |4 oth | |
| 700 | 0 | |a Xiujiang Li |4 oth | |
| 700 | 0 | |a Zhaowei Yan |4 oth | |
| 700 | 0 | |a Jin Zhu |4 oth | |
| 700 | 0 | |a Gang Chen |4 oth | |
| 700 | 0 | |a Zhong Wang |4 oth | |
| 700 | 0 | |a Hualiang Jiang |4 oth | |
| 700 | 0 | |a Liyan Miao |4 oth | |
| 700 | 0 | |a Jian Li |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |d Weinheim : Wiley-VCH, 2006 |g 10(2015), 1, Seite 193 |w (DE-627)506667286 |w (DE-600)2218496-X |w (DE-576)251143732 |x 1860-7179 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2015 |g number:1 |g pages:193 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1002/cmdc.201402386 |3 Volltext |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1639294628 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a VA 3569 |
| 936 | b | k | |a 44.42 |q AVZ |
| 936 | b | k | |a 35.07 |q AVZ |
| 936 | b | k | |a 58.28 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 10 |j 2015 |e 1 |h 193 | ||